339 related articles for article (PubMed ID: 10934140)
1. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.
Galvin JE; Giasson B; Hurtig HI; Lee VM; Trojanowski JQ
Am J Pathol; 2000 Aug; 157(2):361-8. PubMed ID: 10934140
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies.
Neumann M; Adler S; Schlüter O; Kremmer E; Benecke R; Kretzschmar HA
Acta Neuropathol; 2000 Nov; 100(5):568-74. PubMed ID: 11045680
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome).
Haraguchi T; Terada S; Ishizu H; Yokota O; Yoshida H; Takeda N; Kishimoto Y; Katayama N; Takata H; Akagi M; Kuroda S; Ihara Y; Uchitomi Y
Neuropathology; 2011 Oct; 31(5):531-9. PubMed ID: 21276079
[TBL] [Abstract][Full Text] [Related]
4. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
5. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein.
Arawaka S; Saito Y; Murayama S; Mori H
Neurology; 1998 Sep; 51(3):887-9. PubMed ID: 9748051
[TBL] [Abstract][Full Text] [Related]
6. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
7. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
Galvin JE; Uryu K; Lee VM; Trojanowski JQ
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341
[TBL] [Abstract][Full Text] [Related]
8. Tau-predominant-associated pathology in a sporadic late-onset Hallervorden-Spatz syndrome.
Zarranz JJ; Gómez-Esteban JC; Atarés B; Lezcano E; Forcadas M
Mov Disord; 2006 Jan; 21(1):107-11. PubMed ID: 16114023
[TBL] [Abstract][Full Text] [Related]
9. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
[TBL] [Abstract][Full Text] [Related]
10. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.
Duda JE; Giasson BI; Chen Q; Gur TL; Hurtig HI; Stern MB; Gollomp SM; Ischiropoulos H; Lee VM; Trojanowski JQ
Am J Pathol; 2000 Nov; 157(5):1439-45. PubMed ID: 11073803
[TBL] [Abstract][Full Text] [Related]
11. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders.
Takeda A; Hashimoto M; Mallory M; Sundsumo M; Hansen L; Masliah E
Acta Neuropathol; 2000 Mar; 99(3):296-304. PubMed ID: 10663973
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment.
Mori F; Tanji K; Yoshimoto M; Takahashi H; Wakabayashi K
Exp Neurol; 2002 Jul; 176(1):98-104. PubMed ID: 12093086
[TBL] [Abstract][Full Text] [Related]
13. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
14. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
Giasson BI; Duda JE; Murray IV; Chen Q; Souza JM; Hurtig HI; Ischiropoulos H; Trojanowski JQ; Lee VM
Science; 2000 Nov; 290(5493):985-9. PubMed ID: 11062131
[TBL] [Abstract][Full Text] [Related]
15. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies.
Sharon R; Bar-Joseph I; Mirick GE; Serhan CN; Selkoe DJ
J Biol Chem; 2003 Dec; 278(50):49874-81. PubMed ID: 14507911
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system.
Mori F; Tanji K; Yoshimoto M; Takahashi H; Wakabayashi K
Brain Res; 2002 Jun; 941(1-2):118-26. PubMed ID: 12031554
[TBL] [Abstract][Full Text] [Related]
17. The prion protein in human neurodegenerative disorders.
Kovacs GG; Zerbi P; Voigtländer T; Strohschneider M; Trabattoni G; Hainfellner JA; Budka H
Neurosci Lett; 2002 Sep; 329(3):269-72. PubMed ID: 12183028
[TBL] [Abstract][Full Text] [Related]
18. Mixed multiple system atrophy and progressive supranuclear palsy: a clinical and pathological report of one case.
Takanashi M; Ohta S; Matsuoka S; Mori H; Mizuno Y
Acta Neuropathol; 2002 Jan; 103(1):82-7. PubMed ID: 11837750
[TBL] [Abstract][Full Text] [Related]
19. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient.
van Duinen SG; Lammers GJ; Maat-Schieman ML; Roos RA
Acta Neuropathol; 1999 May; 97(5):533-9. PubMed ID: 10334493
[TBL] [Abstract][Full Text] [Related]
20. Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra.
Galvin JE; Schuck TM; Lee VM; Trojanowski JQ
Exp Neurol; 2001 Apr; 168(2):347-55. PubMed ID: 11259122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
